Art

J-GLOBAL ID：201402205715637602   Reference number：14A0497783

Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn’s disease under scheduled maintenance treatment

計画的維持療法中のクローン病患者における血清インフリキシマブのトラフ値と内視鏡レベルでの活動性との関係

Author (9)： IMAEDA Hirotsugu (Shiga Univ. of Medical Sci., Dep. of Medicine, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  BAMBA Shigeki (Shiga Univ. of Medical Sci., Dep. of Medicine, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  TAKAHASHI Kenichiro (Shiga Univ. of Medical Sci., Div. of Mucosal Immunology, Graduate School, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  FUJIMOTO Takehide (Shiga Univ. of Medical Sci., Div. of Mucosal Immunology, Graduate School, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  BAN Hiromitsu (Shiga Univ. of Medical Sci., Dep. of Medicine, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  TSUJIKAWA Tomoyuki (Shiga Univ. of Medical Sci., Dep. of Medicine, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  SASAKI Masaya (Shiga Univ. of Medical Sci., Dep. of Medicine, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  FUJIYAMA Yoshihide (Shiga Univ. of Medical Sci., Dep. of Medicine, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  ANDOH Akira (Shiga Univ. of Medical Sci., Div. of Mucosal Immunology, Graduate School, Seta-Tukinowa, 520-2192, Otsu, JPN)
Material： Journal of Gastroenterology  (J Gastroenterol)
Volume： 49  Issue： 4  Page： 674-682  Publication year： Apr. 2014 
JST Material Number： Z0748A  ISSN： 0944-1174  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： *infliximab

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=14A0497783&from=J-GLOBAL&jstjournalNo=Z0748A") }}

JST classification (2)： Drug therapy(=pharmacotherapy)for digestive system diseases  (GH05020G) ,  Clinical biopharmacy  (GY01022L)

Reference (34)：

• Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92-101.
• Danese S, Colombel JF, Reinisch W, et al. Review article: infliximab for Crohn’s disease treatment-shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther. 2011;33:857-69.
• Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol. 2010;45:9-16.
• Hanauer SB, Kornbluth AA, Messick J, et al. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010;16(Suppl 1):S1-11.
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9.

Terms in the title (9)： 計画 ,  維持療法 ,  クローン病 ,  患者 ,  血清 ,  インフリキシマブ ,  トラフ値 ,  内視鏡 ,  活動